Diligence memo · auto-generated · as of July 2, 2026

Ambit Biosciences Corp

Ambit Biosciences Corp looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Ambit Biosciences Corp operates in Pharmaceuticals, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Ambit Biosciences Corp has raised $87M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $22M on 2012-10-25.

Most recent recorded round closed around 2012-10-25.

Valuation (modeled)modeled

Provath models Ambit Biosciences Corp at approximately $755M (range $47M–$2.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.02× the median modeled value of Series B Pharmaceuticals companies in 2010–2012 (47 peers) — value vs value, same stage and era. Within the normal band (102% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 7 months.

Last raise 13.7 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 3.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 90% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 86% of those peers.

Closest niche peers: Celator Pharmaceuticals Inc, Kythera Biopharmaceuticals Inc, Palatin Technologies Inc, Pernix Therapeutics Holdings, Inc., CEBIX Inc.

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.